In the last year alone, SurModics Inc. (NASDAQ:SRDX) opened a $41 million pharmaceutical plant, which is bleeding cash, fired its CEO, massively restructured its operations, and now is facing down a potentially nasty proxy fight with an aggressive outside investor.
You certainly can’t accuse Bruce Barclay of standing still. Since SurModics Inc. (NASDAQ: SRDX) named Barclay CEO in 2005, Barclay has reorganized the drug company’s business units, purchased land, signed licensing agreements, acquired several companies and expanded into ophthalmology and drug development. Yet the company, based in Eden Prairie, Minn., still has little to show […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ernie Andberg has a little more free time on his hands these days. The long-time “emerging medical device companies” equity analyst for Feltl & Co. in Minneapolis has not seen a lot of companies emerging lately. In fact, they’ve been disappearing all together. Case in point: Medtronic Inc.’s (NYSE: MDT) deal last week to acquire […]